The PRAC Committee reviewed the known association between bleeding events and the use of selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), vortioxetine, and additional data from several observational studies (Bruning et al 2015 and Jiang et al 2016, as well as from Heller at al 2017, Huybrechts at al 2020, Palmsten et al in 2013 and 2020 and Skalkidou et al in 2020) on the occurrence of postpartum hemorrhage in connection with the use of antidepressants by pregnant women, especially SSRIs and SNRIs.
Based on the evidence analyzed, there is currently no need to update the instructions for medical use of medicinal products containing mirtazapine, trazodone, amitriptyline, and bupropion (including its combination with naltrexone). The registration certificate holder of the innovator medicinal product amitriptyline (Lundbeck) is asked to monitor bleeding and postpartum hemorrhage in the next PSUSA procedure. The wording already agreed for duloxetine remains appropriate.
The PRAC considered the comments on the proposed wording received from the registration certificate holders of the innovator products to which this procedure relates, as well as their discussion of the frequency of postpartum hemorrhage. The PRAC agreed that registration certificate holders of medicinal products containing escitalopram, paroxetine, sertraline, venlafaxine should submit, within 2 months from the publication of the PRAC recommendations, amendments to the instructions for medical use (new text underlined):
- in the section “special warnings and precautions for use” – SSRIs/SNRIs may increase the risk of postpartum hemorrhage (see sections “Use during pregnancy and breastfeeding”, “Adverse reactions”);
- in the section “use during pregnancy and breastfeeding” – observational data indicate an increased risk (less than 2 times) of postpartum hemorrhage after exposure to SSRIs/SNRIs during the month before birth (see the sections “special warnings and precautions for use”, “adverse reactions”);
- in the section “adverse reactions” – under disorders of the reproductive system and breast, add postpartum hemorrhage⃰ with a frequency of not known.
⃰ this manifestation has been reported for the therapeutic class of SSRIs/SNRIs (see sections “Special warnings and precautions for use”, “Use during pregnancy and breastfeeding”).
Linkhttps://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-28-september-1-october-2020-prac-meeting_en.pdf
List of medicinal products containing escitalopram, paroxetine, sertraline, venlafaxine and authorized for medical use in Ukraine (according to the State Register of Medicinal Products as of 22.10.2020)